摘要
肠缺血再灌注损伤(IRI)可致多器官功能障碍,但现有治疗手段疗效有限、围术期死亡率极高。随着对肠IRI治疗研究的不断深入,间充质干细胞(MSC)有望成为肠IRI的新兴治疗手段。MSC包括骨髓MSC、脂肪MSC、脐血MSC、羊水MSC等,不同来源的MSC在治肠IRI上有各自的特点。
Intestinal ischemia-reperfusion injury(IRI)can cause multiple organ dysfunctions,the efficacy of existing treatment options are limited and perioperative mortality remains unacceptably high.With the continuous progress in research on intestinal IRI treatment,mesenchymal stem cells(MSC)are expected to become an emerging treatment for intestinal IRI.MSCs include bone marrow MSC,adipose-derived MSC,human umbilical cord blood MSC and amniotic fluid MSC.MSCs from different sources have their own characteristics in the treatment of intestinal IRI.
作者
万占海
石亚静
Wan Zhan-hai;Shi Ya-jing(Department of Anesthesiology,The First Hospital of Lanzhou University,Lanzhou 730000,China;The First School of Clinical Medicine,Lanzhou University,Lanzhou 730000,China)
出处
《兰州大学学报（医学版）》
2022年第9期88-91,94,共5页
Journal of Lanzhou University（Medical Sciences）
基金
国家自然科学基金资助项目(81960345)
甘肃省自然科学基金资助项目(21JR11RA097)
兰州大学第一医院院内基金资助项目(ldyyyn2020-145)。
关键词
间充质干细胞
肠缺血再灌注损伤
治疗
mesenchymal stem cell
intestinal ischemia-reperfusion injury
treatment
